NewLink Genetics Corporation is working on developing a treatment for the Zika virus.
“NewLink Genetics is committed to developing a vaccine solution to the tragedy of the Zika virus disease,” Dr. Thomas Monath, chief scientific officer of NewLink Genetics’ Infectious Disease Division, said. “Our R&D group has decades of experience in developing successful vaccines against closely related flaviviruses, which we will leverage to accelerate our Zika vaccine program.”
The World Health Organization recently declared a state of emergency because of the virus, which is spreading rapidly throughout Latin America. Recent cases have also been reported in the U.S. Virgin Islands. The virus is known to cause microcephaly in newborn babies, which causes newborns to have unusually small heads.
“Given the deep expertise and experience of Dr. Monath and our infectious disease team, we believe we are well positioned to develop a vaccine candidate for the Zika virus,” Dr. Charles Link, CEO of NewLink Genetics, said. “Our team gained considerable experience during the Ebola crisis collaborating with national and international partners in a rapidly evolving public health environment.”
The Infectious Disease Division research team is responsible for working on the treatment. The team is researching several approaches to find a solution as quickly as possible.